Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The CRUK Oxford Centre is pleased to announce the appointment of Professor Tim Elliott as its new co-Director.

Professor Tim Elliot smiling © CRUK

Tim will work alongside Professor Mark Middleton who has filled the role since 2017, to develop and deliver the research strategy for the Oxford Centre.

Professor Tim Elliott is taking over from Professor Xin Lu, who is stepping down after over 3 successful years in the post. During her tenure, Xin has led a step change in the coordination and integration of research efforts across the city. Under Xin’s leadership, a collaborative network of early cancer detection researchers across Oxford has been established and supported through the formation of the Oxford Centre for Early Cancer Detection (OxCODE). As well as providing a forum to stimulate and catalyse research in this critically important research field, significant programmatic funding has been obtained, including for liver (DeLIVER – Prof. Ellie Barnes) and lung (DART – Prof. Fergus Gleeson) cancers, along with numerous seed and project external funding awards in early detection. Xin will continue to play a major role in directing and supporting the CRUK Oxford Centre strategy in her continuing positions as OxCODE Director, NIHR Oxford BRC Cancer Theme Co-Lead and Director of the Ludwig Institute for Cancer Research, Oxford Branch.

Read the full article on the Cancer Research UK website

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.